AtrimusRx AB is a pioneering Swedish life science company revolutionizing personalized medicine. As the first entity in Sweden to secure Medical Products Agency approval for commercial 3D-printed pharmaceuticals, the company has transitioned additive manufacturing from lab environments into active clinical practice. Operating at TRL 9, AtrimusRx delivers custom dosages tailored for pediatrics, adult care, and clinical trials via its innovative Atrimus Px framework. Validating its position in the European ecosystem, AtrimusRx is the selected Swedish partner in the EU4Health-funded RoboPharma project, developing agile, automated, and localized pharmaceutical manufacturing solutions to strengthen healthcare resilience and secure critical supply chains.
